Riber reduces 2018 revenue guidance from €35m to €31m after deferral of two system deliveries to Q1/19

Following the deferral of deliveries for two systems to first-quarter 2019, Riber S.A. of Bezons, France – which manufactures molecular beam epitaxy (MBE) systems as well as evaporation sources and effusion cells – is reducing its revenue forecast for full-year 2018 from €35m to €31m (albeit still up on €30.6m for 2017).

Income from ordinary operations expected for 2018 will be affected by this deferral of revenue and the corresponding margin, as well as by an unexpected increase in costs, particularly for the firm’s subsidiaries, including the creation of the Chinese subsidiary. However, income from ordinary operations will continue to show a profit.

Riber says that this information does not change its strategy, backed by an order book of about €30m at the end of 2018.

See related items:

Riber grows revenue 42% year-on-year for the first nine months of 2018, driven by MBE systems sales almost tripling

Riber’s first-half revenue grows 36% year-on-year as MBE system sales quadruple

Riber’s Q1 revenue down 21.7% year-on-year due to staggering of evaporator deliveries

Riber returns to annual profit

Tags: Riber MBE

Visit: www.riber.com